Yoon Suk Ran, Kim Tae-Don, Choi Inpyo
1] Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea [2] Department of Functional Genomics, Korea University of Science and Technology, Daejeon, Republic of Korea.
Exp Mol Med. 2015 Feb 13;47(2):e141. doi: 10.1038/emm.2014.114.
Cancer cells and the immune system are closely related and thus influence each other. Although immune cells can suppress cancer cell growth, cancer cells can evade immune cell attack via immune escape mechanisms. Natural killer (NK) cells kill cancer cells by secreting perforins and granzymes. Upon contact with cancer cells, NK cells form immune synapses to deliver the lethal hit. Mature NK cells are differentiated from hematopoietic stem cells in the bone marrow. They move to lymph nodes, where they are activated through interactions with dendritic cells. Interleukin-15 (IL-15) is a key molecule that activates mature NK cells. The adoptive transfer of NK cells to treat incurable cancer is an attractive approach. A certain number of activated NK cells are required for adoptive NK cell therapy. To prepare these NK cells, mature NK cells can be amplified to obtain sufficient numbers of NK cells. Alternatively, NK cells can be differentiated and amplified from hematopoietic stem cells. In addition, the selection of donors is important to achieve maximal efficacy. In this review, we discuss the overall procedures and strategies of NK cell therapy against cancer.
癌细胞与免疫系统密切相关,相互影响。尽管免疫细胞可以抑制癌细胞生长,但癌细胞能够通过免疫逃逸机制逃避免疫细胞的攻击。自然杀伤(NK)细胞通过分泌穿孔素和颗粒酶来杀死癌细胞。与癌细胞接触时,NK细胞形成免疫突触以给予致命一击。成熟的NK细胞由骨髓中的造血干细胞分化而来。它们迁移至淋巴结,在那里通过与树突状细胞的相互作用而被激活。白细胞介素-15(IL-15)是激活成熟NK细胞的关键分子。过继性转移NK细胞来治疗无法治愈的癌症是一种有吸引力的方法。过继性NK细胞疗法需要一定数量的活化NK细胞。为了制备这些NK细胞,可以扩增成熟NK细胞以获得足够数量的NK细胞。或者,NK细胞可以从造血干细胞分化并扩增而来。此外,选择供体对于实现最大疗效很重要。在本综述中,我们讨论了NK细胞抗癌治疗的总体程序和策略。